At a quick glance at its one-year chart, seemingly everything about dermatology specialist Cutera (NASDAQ:CUTR) screams danger. Typically, a publicly traded firm doesn’t lose over 88% of its market value over a 52-week period unless something catastrophic happens. Despite the awful print, however, Cutera is involved in a relevant industry. Combined with its short squeeze potential, CUTR stock could be intriguing for contrarian speculators.According to its public profile, Cutera develops and markets so-calle ...